Mozoly tablets 5mg Cadila treat heartburn, nausea, gastroesophageal reflux - esophagus (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Mosapride citrate

Ingredient

Composition information	Content
Mosapride citrate	5mg

Uses

indications

Mozoly 5 is indicated in the following cases: Treatment of symptoms of gastrointestinal tract ( heartburn , vomiting/vomiting) to gastroesophageal reflux esophagus.

Pharmacology

Mosaprid is a replacement benzamid derivative with the characteristics of gastric activity enhancement, thus increasing stomach motility and empty stomach.

Mechanism of impact:

This drug is a selective 5-HT receptor. It is believed that this drug stimulates 5-HT receptors in the digestive nerve puppet, and this increases the release of acetylcholin, leading to an increase in stomach peristalsis and increasing emptiness.Clinical pharmacology:

In clinical pharmacological studies in healthy subjects and patients with chronic gastritis, the single dose of these 5 mg increases stomach emptiness.

Effectiveness increases stomach movement:

This drug increases the process of empty and duodenum after meals in volunteers. Less influence in colon circulation.

The effect on increasing the ability to empty the stomach:

This drug increases the stomach empty of liquid and solid food. Effects increases stomach drums decreased after 1 week of repeating treatment.

Mosaprid's ability, a substance that increases intestinal motility, connected to a 5-HT4 receptor surveyed in human stomach and white mouse experimental by taking in vitro receptors.

The positions mounted [1251] SB267710 were discovered in the muscle layer including the stomach's intestinal muscle reflexes in both humans and experimental mice, although the cohesion is more clear and more in the stomach of the experimental mouse than in humans.

The effect of mosaprid on esophageal reflux parameters within 24 hours is studied in 21 patients with symptoms and the total exposure time for acid before participating in the study is more than 5%.

Dynamic pharmacokinetics

Dynamic pharmacokinetics and dose ratio of Mosapid Cirat ((+-)-4-amino-5-chloro2-eloxy-n-[[4- (4-fluorobenzyl) -2-morphinyl] methyl] Benzamid Citrate dihydrate, AS4370, CAS112885-42-4-4- Healthy volunteering.

In human clinical studies, the subjects studied single oral doses (5, 19, 20 and 40 mg, each group of 5 people) and each multiple oral dose (20 mg 3 times daily for a day, and 10 and 20 mg 3 times daily for 8 days, each group of 5 people).

The effect of food on Mosaprid's pharmacokinetics has also been evaluated after a single 10 mg oral dose with an open method, crossing 2 ways. The average plasma concentration of Mosaprid reaches a peak of 0.5-1 h after the single dose 5, 10, 20 and 40 mg. The peaks in plasma are achieved with values in the order of 25,1, 51,2, 157,8 and 280.6 ng/ml, and followed by the first reduction with clear selling time of 1.4-2.0 hours.

CMAX and AUC increased by dose, indicating the linear pharmacokinetics of Mosaprid up to 40 mg. The CMAX of M-1, a DES-4-Fluorobenzyl metabolic metabolite, accounts for 1/6 of the metabolites under constant. The mosaprid part is unchanged through the urinary tract and M-1 for 48 hours after the single dose accounts for 0.1-0.4% and 7.0-11.0% of the dose.

There is no significant change in the attribute of the drug concentration in soy-time-duration of the urinary tract between the doses and the multiple doses, indicating that the pharmacokinetics of the mosaprid in humans is not changed by the multi-dose use. Plasma mosaprid concentrations achieve a stable state on the second day of multi -dose use.

Before taking Mozoly tablets 5mg Cadila treat heartburn, nausea, gastroesophageal reflux - esophagus (3 blisters x 10 tablets)

How to use

oral medication.

Dosage

For adults: Use 1 tablet (5 mg of mosaprid citrate) 3 times a day, can be taken before or after meals.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

Not yet studied.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Do not drink twice as prescribed.

Side Effects

When using Mozoly 5 , you may experience unwanted effects (ADR).

Sidominal reactions are observed in 40 of 998 patients (4%) in lonely trials. The main reactions are liquid diarrhea (1.8%), dry mouth (0.5%), depression (0.3%). The abnormal values observed in the laboratory are 30 out of 792 (3.8%) of cases and include cases of increasing eosinophil (1.1%), triglyceride (1.0%), GOT, GPT, ALP and Y-GTP (each case 0.4%).

Notify the doctor the unwanted effects when using the drug.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Mozoly medicine 5

Caution when using

Precautions: If the treatment is not effective after two weeks, it is advisable to stop treatment.

Use in children: Not safe for children under 13 years old.

Used in older adults: Careful consideration in older patients. Any adverse reaction is appropriate, such as reducing treatment dose.

The ability to drive and operate machinery

has not yet seen any impact.

Pregnancy

only use this drug for pregnant women when the benefits are superior to the risk of possible (unknown safety of the drug in pregnant and lactating women).

The period of breastfeeding

Avoid prescribing this medication for breastfeeding women. If necessary, the mother should stop breastfeeding during treatment (research in rabbits shows this drug in milk).

Drug interaction

should be cautious when used simultaneously with the following drugs:

Atropin sulphat butylscopolamin bromid): Due to the effect of increasing the intestinal motility of this drug, it has been activated by the activity of the sympathetic system, so the simultaneous use of sympathetic antagonists can reduce the effectiveness of this drug.

Storage

Avoid light, temperature below 30 ° C.

Expiry date: 36 months from the date of production.

Do not use overdue drugs indicated on the packaging.

Manufacturer: Cadila Pharmaceuticals Limited.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.